FiercePharma | Nachrichten

Zeit	Aktuelle Nachrichten
Fr	Jeans and other drugs: Novartis CEO Narasimhan's prescription for a millennial-friendly culture
Fr	AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fr	Tris Pharma recalls potentially harmful infants' ibuprofen
Fr	With pricing outcry raging, U.S. drug spending grew less than 1% last year: CMS
Fr	With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up?
Fr	FiercePharmaAsia-Takeda-Shire finish line; Sun's crisis; J&J-Legend CAR-T
Fr	Roche's Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck
Fr	Actelion inks $360M deal to resolve DOJ kickbacks probe
Do	Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image
Do	BREAKING: Actelion inks $360M deal to resolve DOJ kickbacks probe
Do	Big pharma's off-patent drugs lose out in China's new price-cutting scheme
Do	Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount
Do	Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court
Do	Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3
Do	News of Note - Mylan now recalling 104 lots of valsartan medications
Do	Sanofi plots 670 layoffs in France as local tensions brew
Do	Roche's Tecentriq lines up for billion-dollar market with FDA priority tag
Do	Catalent is expanding and adding 36 jobs at its Indiana biologics plant
Mi	Novo keeps adding capacity, and jobs, to its North Carolina drug plant
Mi	AstraZeneca's Calquence found success in lymphoma. Will CLL follow?
Mi	Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'
Mi	Chinese drugmaker pours $145M into plant with plan to produce innovative biologics
Mi	Takeda CEO gets his Shire megamerger, thanks to shareholder nod. Can he make it pay off?
Mi	News of Note - Gardasil-Cervarix divide, flu vaccines and more
Mi	Mismanagement allegations send Sun Pharma stock tumbling: What we know so far

Zeit

Aktuelle Nachrichten

Jeans and other drugs: Novartis CEO Narasimhan's prescription for a millennial-friendly culture

AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer

Tris Pharma recalls potentially harmful infants' ibuprofen

With pricing outcry raging, U.S. drug spending grew less than 1% last year: CMS

With Tesaro off the block, will Clovis be the next PARP maker to get swallowed up?

FiercePharmaAsia-Takeda-Shire finish line; Sun's crisis; J&J-Legend CAR-T

Roche's Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck

Actelion inks $360M deal to resolve DOJ kickbacks probe

Troubled Mallinckrodt spins off specialty generics business in ongoing effort to reshape its image

BREAKING: Actelion inks $360M deal to resolve DOJ kickbacks probe

Big pharma's off-patent drugs lose out in China's new price-cutting scheme

Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount

Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court

Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3

News of Note - Mylan now recalling 104 lots of valsartan medications

Sanofi plots 670 layoffs in France as local tensions brew

Roche's Tecentriq lines up for billion-dollar market with FDA priority tag

Catalent is expanding and adding 36 jobs at its Indiana biologics plant

Novo keeps adding capacity, and jobs, to its North Carolina drug plant

AstraZeneca's Calquence found success in lymphoma. Will CLL follow?

Taking aim at Medicaid misclassifications like Mylan's EpiPen, senators look to end a 'pharma ripoff'

Chinese drugmaker pours $145M into plant with plan to produce innovative biologics

Takeda CEO gets his Shire megamerger, thanks to shareholder nod. Can he make it pay off?

News of Note - Gardasil-Cervarix divide, flu vaccines and more

Mismanagement allegations send Sun Pharma stock tumbling: What we know so far

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von FiercePharma